We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+49.06%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$459M
AUM Growth
+$82.8M
Cap. Flow
-$20.4M
Cap. Flow %
-4.45%
Top 10 Hldgs %
57.01%
Holding
59
New
13
Increased
17
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$7.18M
2
CMPX icon
Compass Therapeutics
CMPX
+$5.48M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$4.65M
4
NTLA icon
Intellia Therapeutics
NTLA
+$4.33M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.14M

Top Sells

Rank Stock Value
1
SLRN
ACELYRIN
SLRN
+$19.5M
2
IDYA icon
IDEAYA Biosciences
IDYA
+$11.1M
3
BHVN icon
Biohaven
BHVN
+$8.56M
4
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.33M
5
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$6.13M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPTX
51
DELISTED
Repare Therapeutics
RPTX
$318K 0.07%
+67,561
New +$433K
ARQT icon
52
Arcutis Biotherapeutics
ARQT
$3.13B
– –
-1,960,000
Closed -$6.33M
BHVN icon
53
Biohaven
BHVN
$2.43B
– –
-200,000
Closed -$8.56M
IDYA icon
54
IDEAYA Biosciences
IDYA
$4.03B
– –
-311,500
Closed -$11.1M
KALV
55
DELISTED
KalVista Pharmaceuticals
KALV
– –
-150,000
Closed -$1.84M
KNSA icon
56
Kiniksa Pharmaceuticals
KNSA
$6.23B
– –
-37,500
Closed -$640K
STRO icon
57
Sutro Biopharma
STRO
$353M
– –
-30,149
Closed -$1.29M
MRNS
58
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-563,500
Closed -$6.13M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2024 Portfolio in Review

As of Q1 2024, Opaleye Management held 59 positions worth $459M, up 22% from $376M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Opaleye Management withdrew a net $20.4M in Q1 2024, closing 7 positions and reducing 15 holdings. Its most notable exit was IDEAYA Biosciences, an estimated $11.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Lyell Immunopharma worth $7.48M.

  • Opaleye Management's largest Q1 2024 buy was Lyell Immunopharma: 167,750 shares worth $7.48M.
  • Opaleye Management added most to Intellia Therapeutics in Q1 2024, an estimated $4.33M increase.
  • Opaleye Management's biggest Q1 2024 reduction was ACELYRIN, cutting an estimated $19.5M.
  • Opaleye Management fully exited IDEAYA Biosciences in Q1 2024, selling an estimated $11.1M.
  • Opaleye Management's ten largest holdings make up 57% of its $459M portfolio in Q1 2024.
  • Opaleye Management opened 13 new positions and closed 7 in Q1 2024.
  • Opaleye Management's portfolio value rose 22% quarter-over-quarter to $459M.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.